Syndax Pharmaceuticals is a commercial-stage biotech focused on oncology and related immunology. Its portfolio includes revumenib, a menin inhibitor approved for genetically defined acute leukemias, and axatilimab (Niktimvo), developed with Incyte for chronic graft-versus-host disease. The company targets hard-to-treat cancers and immune complications with mechanism-based small molecules and antibodies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 38 | — | -71.8 | — |
| Q3 2025 | 45.9 | — | -60.7 | — |
| Q4 2025 | 68.7 | — | -68 | — |
| Q1 2026 | 64.9 | — | -42.7 | — |
| Q2 2026 | 72.8 | 91.8% | -49.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Radware Ltd. (RDWR), OPKO Health, Inc. (OPK), Damora Therapeutics, Inc. (DMRA), TMC the metals company Inc. (TMC), Univest Financial Corporation (UVSP), Alpha Tau Medical Ltd. (DRTS)